Nanobiotix S.A Net Cash Flow 2020-2024 | NBTX

Nanobiotix S.A net cash flow from 2020 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.

Nanobiotix S.A Net Cash Flow 2020-2024 | NBTX

Nanobiotix S.A net cash flow from 2020 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$70.5B
Zoetis (ZTS)$69.4B
Takeda Pharmaceutical (TAK)$49.4B
Daiichi Sankyo, - (DSNKY)$48.3B
BeOne Medicines - (ONC)$34.4B
Sandoz Group AG (SDZNY)$27.6B
Summit Therapeutics (SMMT)$19.5B
Merck (MKKGY)$17B
Shionogi (SGIOY)$14.9B
United Therapeutics (UTHR)$14.1B
Neurocrine Biosciences (NBIX)$13.4B
IPSEN (IPSEY)$11.4B
Orion OYJ (ORINY)$11.3B
Eisai (ESAIY)$9.3B
Madrigal Pharmaceuticals (MDGL)$9.2B
Corcept Therapeutics (CORT)$7.4B
Grifols, S.A (GRFS)$7B
Stevanato Group S.p.A (STVN)$6.9B
Ionis Pharmaceuticals (IONS)$6.8B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
Procaps Group, S.A (PROCF)$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.6B
Hypermarcas (HYPMY)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B